Sagimet Biosciences Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| SGMT | IVA | SABS | VSTM | SLDB | GPCR | |
|---|---|---|---|---|---|---|
| Market cap | 708.38M | 914.17M | 289.34M | 1.20B | 699.11M | 1.45B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -7.7 | -5.2 | -3.3 | -8.1 | -3.8 | -9.6 |
| Price/book | 2.4 | 13.8 | 1.2 | 17.8 | 2.9 | 1.1 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +28.06% | −7.42% | −1.89% | +19.73% | +54.69% | −36.82% |
| Today | +0.40% | −3.97% | +1.92% | +0.82% | +3.82% | +0.05% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All SGMT news ›Dermata Therapeutics, Inc. (DRMA) Starts Acne Trial, Targets H1 2027 Launch
TradingView Dermata Therapeutics, Inc. (DRMA) Starts Acne Trial, Targets H1 2027 Launch Dermata Therapeutics enrolled the first participant in an open-label trial of its once-weekly Tome Clearing Treatment for acne, aiming
Ascletis Pharma Partner Starts U.S. Phase 3 Trial of Acne Drug
Ascletis Pharma said its strategic partner, Sagimet Biosciences, has dosed the first patient in a U.S. Phase 3 clinical trial of denifanstat for moderate-to-severe acne in adults and adolescents... Ascletis Pharma Partner Starts U.S. Phase…
Sagimet Biosciences Inc. (SGMT) – What Are Analysts Saying About This Stock?
Posted by Danessa Lincoln on Oct 27th, 2026 Check Out Our Latest Stock Analysis on SGMT Sagimet Biosciences stock opened at $9.56 on Tuesday. The firm has a market capitalization of $594.25 million, a P/E ratio of -7.47 and a beta of 3.46.…
Sagimet Biosciences: The U.S. Acne Trial Is A Replication Exercise, Not A Discovery Bet
Seeking Alpha - Sagimet Biosciences pivots denifanstat to acne, with robust Phase 3 data and a fully funded U.S. registrational trial underway. - SGMT trades below cash value, presenting an asymmetric risk/reward
Sagimet Biosciences Updates Pipeline: Acne Phase 3 Underway, TVB-3567 Phase 2 Planned
TradingView Sagimet Biosciences Updates Pipeline: Acne Phase 3 Underway, TVB-3567 Phase 2 Planned Sagimet Biosciences updated its investor presentation, highlighting progress in acne trials and funding expected to
Sagimet Biosciences starts key Phase 3 trial for acne drug denifanstat in the U.S.
Sagimet Biosciences has initiated a crucial Phase 3 clinical trial in the U.S. for denifanstat, an oral treatment targeting moderate to severe acne. The trial, named AURORA, aims to enroll around 800 patients, including adolescents, to…
Head-To-Head Review: Sagimet Biosciences (NASDAQ:SGMT) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA)
Posted by Defense World Staff on Oct 19th, 2026 Kiniksa Pharmaceuticals International (NASDAQ:KNSA – Get Free Report) and Sagimet Biosciences (NASDAQ:SGMT – Get Free Report) are both healthcare companies, but which is the superior…
Zhejiang Asia Pacific eyes Fudan-linked acne therapy in preliminary technology deal
AllSci R&D and approval milestone payments total RMB 25 million, with commercialization milestones capped at RMB 40 million; the 2% annual net sales share accrues for ten years from market launch or until patent expi
Dermata Therapeutics Announces Positive Topline Results from Cosmetic Study Evaluating Its Tome Foundational Treatment
Profusa Receives ISO 13485:2016 Certificate from GMED Consumers can purchase four weekly treatments at once or choose a subscription at a discounted price. On Oct 15, the day this news came out, the latest delayed price for DRMA is 4.64%…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- stocktitan.net2
- tradingview.com2
- defenseworld.net1
- markets.businessinsider.com1
- markets.financialcontent.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 12 articles, not a forecast.